Polar Asset Management Partners Inc. Takes $7.80 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Polar Asset Management Partners Inc. purchased a new position in United Therapeutics Co. (NASDAQ:UTHR) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,100 shares of the biotechnology company’s stock, valued at approximately $7,798,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in UTHR. Wealthfront Advisers LLC boosted its holdings in United Therapeutics by 2,090,573.5% in the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock worth $6,462,018,000 after acquiring an additional 18,313,424 shares in the last quarter. Norges Bank bought a new position in United Therapeutics in the fourth quarter worth approximately $151,764,000. FMR LLC boosted its holdings in United Therapeutics by 36.5% in the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock worth $519,170,000 after acquiring an additional 393,777 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in United Therapeutics by 1,325.5% in the fourth quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company’s stock worth $72,085,000 after acquiring an additional 189,967 shares in the last quarter. Finally, AustralianSuper Pty Ltd boosted its holdings in United Therapeutics by 577.1% in the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock worth $66,962,000 after acquiring an additional 161,751 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $300.93, for a total value of $3,310,230.00. Following the completion of the transaction, the executive vice president now directly owns 36,781 shares in the company, valued at approximately $11,068,506.33. The trade was a 23.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Raymond Dwek sold 3,000 shares of the business’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $285.57, for a total value of $856,710.00. Following the transaction, the director now owns 1,750 shares of the company’s stock, valued at approximately $499,747.50. The trade was a 63.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 45,500 shares of company stock valued at $13,447,180 over the last ninety days. 10.30% of the stock is currently owned by insiders.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $307.65 on Monday. The business has a fifty day simple moving average of $299.63 and a two-hundred day simple moving average of $337.46. United Therapeutics Co. has a 1 year low of $264.33 and a 1 year high of $417.82. The company has a market capitalization of $13.88 billion, a P/E ratio of 13.51, a P/E/G ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same period last year, the business posted $6.17 earnings per share. The business’s revenue for the quarter was up 17.2% on a year-over-year basis. As a group, analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Bank of America upgraded United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 target price on the stock in a report on Monday, April 21st. Wells Fargo & Company restated an “equal weight” rating and issued a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Wall Street Zen lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 2nd. JPMorgan Chase & Co. dropped their target price on United Therapeutics from $355.00 to $350.00 and set an “overweight” rating on the stock in a report on Thursday, May 1st. Finally, Morgan Stanley raised their target price on United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a report on Thursday, May 1st. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $392.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.